全文获取类型
收费全文 | 1030篇 |
免费 | 64篇 |
国内免费 | 16篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 44篇 |
妇产科学 | 7篇 |
基础医学 | 116篇 |
口腔科学 | 14篇 |
临床医学 | 160篇 |
内科学 | 244篇 |
皮肤病学 | 18篇 |
神经病学 | 17篇 |
特种医学 | 128篇 |
外科学 | 79篇 |
综合类 | 111篇 |
预防医学 | 36篇 |
眼科学 | 4篇 |
药学 | 72篇 |
中国医学 | 1篇 |
肿瘤学 | 54篇 |
出版年
2023年 | 2篇 |
2022年 | 9篇 |
2021年 | 14篇 |
2020年 | 6篇 |
2019年 | 8篇 |
2018年 | 10篇 |
2017年 | 13篇 |
2016年 | 15篇 |
2015年 | 23篇 |
2014年 | 35篇 |
2013年 | 28篇 |
2012年 | 43篇 |
2011年 | 39篇 |
2010年 | 45篇 |
2009年 | 43篇 |
2008年 | 51篇 |
2007年 | 40篇 |
2006年 | 33篇 |
2005年 | 35篇 |
2004年 | 36篇 |
2003年 | 38篇 |
2002年 | 23篇 |
2001年 | 37篇 |
2000年 | 35篇 |
1999年 | 30篇 |
1998年 | 51篇 |
1997年 | 45篇 |
1996年 | 31篇 |
1995年 | 20篇 |
1994年 | 29篇 |
1993年 | 26篇 |
1992年 | 8篇 |
1991年 | 14篇 |
1990年 | 23篇 |
1989年 | 22篇 |
1988年 | 21篇 |
1987年 | 31篇 |
1986年 | 11篇 |
1985年 | 14篇 |
1984年 | 6篇 |
1983年 | 9篇 |
1982年 | 14篇 |
1981年 | 6篇 |
1980年 | 5篇 |
1979年 | 2篇 |
1978年 | 8篇 |
1977年 | 6篇 |
1976年 | 8篇 |
1975年 | 6篇 |
1967年 | 2篇 |
排序方式: 共有1110条查询结果,搜索用时 31 毫秒
11.
Survey of CAG/CTG repeats in human cDNAs representing new genes: candidates for inherited neurological disorders 总被引:3,自引:2,他引:3
Neri C; Albanese V; Lebre AS; Holbert S; Saada C; Bougueleret L; Meier-Ewert S; Le Gall I; Millasseau P; Bui H; Giudicelli C; Massart C; Guillou S; Gervy P; Poullier E; Rigault P; Weissenbach J; Lennon G; Chumakov I; Dausset J; Lehrach H; Cohen D; Cann HM 《Human molecular genetics》1996,5(7):1001-1009
12.
Background
The current status of radioiodine-131 (RaI) dosimetry for Graves' hyperthyroidism is not clear. Recurrent hyperthyroidism and iatrogenic hypothyroidism are two problems which interact such that trying to solve one leads to exacerbation of the other. Optimized RaI therapy has therefore begun to be defined just in terms of early hypothyroidism (ablative therapy) as physicians have given up on reducing hypothyroidism.Methods
Optimized therapy is evaluated both in terms of the greatest separation of cure rate from hypothyroidism rate (non-ablative therapy) or in terms of early hypothyroidism (ablative therapy) by mathematical modeling of outcome after radioiodine and critically discussing the three common methods of RaI dosing for Graves' disease.Results
Cure follows a logarithmic relationship to activity administered or absorbed dose, while hypothyroidism follows a linear relationship. The effect of including or omitting factors in the calculation of the administered I–131 activity such as the measured thyroid uptake and effective half-life of RaI or giving extra compensation for gland size is discussed.Conclusions
Very little benefit can be gained by employing complicated methods of RaI dose selection for non-ablative therapy since the standard activity model shows the best potential for cure and prolonged euthyroidism. For ablative therapy, a standard MBq/g dosing provides the best outcome in terms of cure and early hypothyroidism. 相似文献13.
Canfield MC; Tamarappoo BK; Moses AM; Verkman AS; Holtzman EJ 《Human molecular genetics》1997,6(11):1865-1871
Congenital nephrogenic diabetes insipidus (NDI) is a rare disease caused
most often by mutations in the vasopressin V2 receptor (AVPR2). We studied
a family which included a female patient with NDI with symptoms dating from
infancy. The patient responded to large doses of desmopressin (dDAVP) which
decreased urine volume from 10 to 4 I/day. Neither the parents nor the
three sisters were polyuric. The patient was found to be a compound
heterozygote for two novel recessive point mutations in the aquaporin-2
(AQP2) gene: L22V in exon 1 and C181W in exon 3. Residue Cys181 in AQP2 is
the site for inhibition of water permeation by mercurial compounds and is
located near to the NPA motif conserved in all aquaporins. Osmotic water
permeability (Pf) in Xenopus oocytes injected with cRNA encoding C181W-AQP2
was not increased over water control, while expression of L22V cRNA
increased the Pf to approximately 60% of that for wild-type AQP2.
Co-injection of the mutant cRNAs with the wild-type cRNA did not affect the
function of the wild-type AQP2. Immunolocalization of AQP2-transfected CHO
cells showed that the C181W mutant had an endoplasmic reticulum-like
intracellular distribution, whereas L22V and wild-type AQP2 showed endosome
and plasma membrane staining. Water permeability assays showed a high Pf in
cells expressing wild-type and L22V AQP2. This study indicates that AQP2
mutations can confer partially responsive NDI.
相似文献
14.
Reciprocal effect of Waardenburg syndrome mutations on DNA binding by the Pax-3 paired domain and homeodomain 总被引:1,自引:1,他引:1
The Pax-3 protein contains two DNA-binding domains, a paired domain and a
homeodomain. Mutations in Pax-3 cause Waardenburg syndrome (WS) in humans
and the mouse Splotch (Sp) phenotype. In the Sp-delayed mouse, a mutation
in the Pax-3 paired domain (G9R) abrogates the DNA-binding activity of both
the paired domain and the homeodomain, suggesting that they may
functionally interact. To investigate this possibility further, we have
analyzed the DNA-binding properties of additional point mutants in the
Pax-3 paired domain and homeodomain that occur in WS patients (F12L, N14H,
G15S, P17L, R23L, G48A, S51F and G66D in the paired domain, V47F and R53G
in the homeodomain), the Pax-1 un mutation (G15A) and a substitution
associated with Peters' anomaly in the PAX-6 gene (R23G). Within the paired
domain, seven of 10 mutations were found to abrogate DNA-binding by the
paired domain. Remarkably, these seven mutations also affected DNA binding
by the homeodomain, causing either a complete loss (P17L and G66D), a
reduction (R23G, R23L, G15S and G15A) or an increase in DNA-binding
activity (N14H). In addition, the effect of paired domain mutations
occurred at the level of monomer formation by the homeodomain, while the
dimerization potential of this domain seemed unaffected in mutants where it
could be analyzed. Furthermore, while both homeodomain mutations were found
to abolish DNA binding by this domain, the R53G mutation also abrogated DNA
binding by the paired domain. The important observation that independent
mutations in either domain can affect DNA binding by the other in the
intact Pax- 3 protein strongly suggests that the two domains are not
functionally independent but bind DNA through cooperative interactions.
Modeling the deleterlous mutations on the three-dimensional structure of
the paired domain of Drosophila Prd shows that these mutations cluster at
the DNA interface, thus suggesting that a series of DNA contacts are
essential for DNA binding by both the paired domain and the homeodomain of
Pax-3.
相似文献
15.
The prevalence of microalbuminuria was assessed in 50 patients of non-insulin dependent diabetes mellitus. The mean age of patients was 52.1 ± 11.6 years and the duration of diabetes was 8.3 ± 6.8 years. Twenty (40%) patients had microalbuminuria. Microalbuminuria was more common in patients with a longer duration of diabetes (more than 5 years), a poor glycaemic control, and higher systolic blood pressure.KEY WORDS: Microalbuminuria, Diabetes mellitus, Diabetic nephropathy, Chronic renal failure 相似文献
16.
AS Harvey 《Journal of paediatrics and child health》2003,39(8):640-640
17.
18.
CONTEXT: Given the level of unintended pregnancy in the United States, it is somewhat surprising that hormonal implants and injectables-methods that are long-acting, reversible, highly effective and convenient--have not attained the popularity enjoyed by other medical methods. Knowing the reasons why women have so far spurned these methods might lead to the design and implementation of interventions and targeted social marketing to promote their use. METHODS: Data from the 1993 and 1995 rounds of the National Survey of Women are used to examine the reasons women gave for not having used the implant or injectables, whether they intended to use these methods and how their attitudes toward them may influence their decision to use such methods in the future. Logistic regression models were used to identify the social and demographic characteristics that influence women's decisions not to use these methods. RESULTS: Fewer than 2% of women who were at risk of an unintended pregnancy in 1995 were using the implant, and under 3% were using the injectable. Women gave three major reasons for not using either of these methods: lack of knowledge; fear of side effects or health hazards; and satisfaction with the method they were currently using. Age, education, marital status, parity and current contraceptive method strongly predicted fear of side effects, lack of knowledge and satisfaction with the current method as reasons for not using the implant or the injectable. For example, women aged 30 or older and those with a college education were half as likely as younger women and those with no college education to mention fear of side effects as their main reason for not using the implant. Likewise, single women, women with one or more children and those using a barrier method were 2-3 times as likely as married women, childless women and those using a medical method to attribute nonuse to the implant's side effects. Few women said they intended to use these methods in the next 12 months: 5% for the implant and 10% for the injectable. Single women, women with no college education, women with children, women wanting to have a child (or another child) and women with positive attitudes toward the effect of using an injectable were significantly more likely to say they intended to use the injectable. Nevertheless, substantial proportions of women reported quite negative attitudes about these methods. CONCLUSIONS: The low prevalence of use and the low level of use intention for the implant and for injectables raise questions about the promise for the future of these methods. Each method seems to appeal to certain subgroups of women, however. Thus, if proper interventions and social marketing are targeted to such groups, they may be disabused of misperceptions regarding these methods and possibly become more willing to try them. 相似文献
19.
WF Paterson E McNeill S Reid AS Hollman MD Donaldson 《Archives of disease in childhood》1998,79(4):323-327
OBJECTIVE: To assess the efficacy of a longer acting preparation of the gonadotrophin releasing hormone (GnRH) analogue goserelin (Zoladex LA, 10.8 mg) in 12 girls with central precocious or early puberty. METHODS: Two girls started treatment de novo; the remainder had been on suppressive treatment for a median duration of 1.5 (range, 0.2-5.6) years. Assessment comprising auxology, pubertal staging, and pelvic ultrasound examination was carried out at weeks 0, 4, 8, 10, and 12 (first cycle) and weeks 8, 10, and 12 (second cycle) to evaluate the required injection frequency. Thereafter, assessment was performed on the day of injection. Zoladex LA was given every 12 weeks unless pubertal progression occurred. RESULTS: Satisfactory control was achieved in eight patients using this regimen, and three patients required more frequent injections. One girl was removed from the study because of clinical progression and extreme mood swings. No serious adverse effects occurred. Mean height velocity during the study period was 4.5 cm/year (range, 3.1-6.6) compared with 6.5 cm/year (range, 3.8-9.6) before treatment in nine patients for whom data were available. CONCLUSIONS: Zoladex LA was effective in controlling precocious puberty in girls when given at intervals of 9-12 weeks and it is recommended that an initial assessment is made eight weeks after beginning treatment. 相似文献
20.
Oberyszyn TM; Conti CJ; Ross MS; Oberyszyn AS; Tober KL; Rackoff AI; Robertson FM 《Carcinogenesis》1998,19(3):445-455
The beta2 integrin (CD 18/CD 11 a, b, c) family of proteins mediate
adherence of leukocytes to vascular endothelium and the associated ligand,
intercellular adhesion molecule-1 (ICAM-1; CD 54), interacts with beta2
integrin proteins to allow transendothelial migration of leukocytes into
sites of inflammation. The present study examines the function of these
proteins in a murine model of acute cutaneous inflammation induced
following topical application of 12-O- tetradecanoylphorbol-13-acetate
(TPA) to the dorsal epidermis of SENCAR mice and in a model of skin
multistage carcinogenesis. At 24 h following topical application of TPA to
the dorsal epidermis of mice, dermal leukocytes expressed higher levels of
beta2 integrin protein compared with the lower levels of beta2 integrin
protein expression by peripheral blood leukocytes. ICAM-1 protein was
localized to epidermal keratinocytes and vascular endothelium in
TPA-treated skin and to proliferating papilloma cells. Intravenous (i.v.)
injection of either 50 microg anti-beta2 integrin antibody alone or in
combination with anti-ICAM-1 antibody significantly inhibited both
TPA-stimulated neutrophil infiltration into the dermis (P < 0.001) and
myeloperoxidase (MPO) activity (P < 0.03 anti-beta2 integrin antibody; P
< 0.01 anti- beta2 integrin + ICAM-1 adhesion molecule antibodies), but
had no effect on TPA-induced epidermal hyperplasia. In addition, injection
of either anti-ICAM-1 adhesion molecule antibody alone (P < 0.004) or in
combination with anti-beta2 integrin antibody (P < 0.001) significantly
inhibited TPA-induced production of 7,8-dihydroxy-2'-deoxyguanosine (8-
OHdG) immunoreactive proteins by epidermal keratinocytes. Beta2
integrin/ICAM-1 adhesion molecules work in concert to regulate migration,
retention and functional activation of leukocytes within the dermis during
TPA-induced skin inflammation and within stromal tissue of papillomas that
form during multi-stage carcinogenesis. Agents that inhibit these
receptor/ligand interactions may be useful in defining the roles of
specific cell populations in cutaneous inflammation and multistage
carcinogenesis and may also have potential as anti-promoting and
anti-progression agents.
相似文献